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Abstract
Depressive symptoms vary in severity and chronicity. We used group-based trajectory models to describe trajectories of 
depressive symptoms (measured using the Patient Health Questionnaire-9) and predictors of trajectory group membership 
among 1493 HIV-infected men (84%) and 292 HIV-infected women (16%). At baseline, 29% of women and 26% of men 
had depressive symptoms. Over a median of 30 months of follow-up, we identified four depressive symptom trajectories for 
women (labeled “low” [experienced by 56% of women], “mild/moderate” [24%], “improving” [14%], and “severe” [6%]) and 
five for men (“low” [61%], “mild/moderate” [14%], “rebounding” [5%], “improving” [13%], and “severe” [7%]). Baseline 
antidepressant prescription, panic symptoms, and prior mental health diagnoses were associated with more severe or dynamic 
depressive symptom trajectories. Nearly a quarter of participants experienced some depressive symptoms, highlighting the 
need for improved depression management. Addressing more severe or dynamic depressive symptom trajectories may require 
interventions that additionally address mental health comorbidities.
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Introduction
Depression is the most commonly reported mental health 
condition among people living with HIV (PLWH), affect-
ing 20–30% of HIV-infected adults in the United States [1, 
2]. For PLWH, depression negatively impacts quality of 
life [3, 4], antiretroviral therapy (ART) adherence [5, 6], 
viral suppression [7–9], and long-term survival, and it has 
been linked to sexual transmission risk behavior [7, 10–15]. 
Despite numerous calls to improve depression treatment 
[16, 17] and the availability of effective depression treat-
ment interventions [18–22], depression remains a critical 
issue affecting quality of life and HIV outcomes for PLWH.
Understanding patterns of depressive symptom presence 
and severity over time may help to improve the manage-
ment of depressive symptoms for HIV-infected adults. Many 
studies implicitly treat different levels and trajectories of 
depression as the same, measuring the prevalence of depres-
sive symptoms at one time point and categorizing partici-
pants dichotomously as either depressed or not depressed 
[23–27]. However, the clinical manifestation of depression is 
often more complex. Depressive symptoms may change over 
time and be reoccurring, particularly among PLWH [28–30]. 
Similarly, heterogeneity in severity of depressive symptoms 
exists, with more severe depressive symptoms correlating 
with increased risk behaviors and lower CD4 counts in HIV-
infected adults [31]. Given the complex nature of depression, 
a more nuanced picture of how individuals who follow simi-
lar patterns of depressive symptoms cluster over time may 
help to guide clinical management.
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In this analysis, we use data from a large cohort of HIV-
infected adults in routine HIV care to describe distinct tra-
jectories of depressive symptoms over time and to explore 
characteristics associated with membership in each trajec-
tory. Our analysis provides a longitudinal view of depressive 
symptoms in which the time origin varies across individuals 
with respect to time since HIV diagnosis, HIV care entry, 
and depression emergence. Although more meaningful 
trajectory origins may be identified from a developmen-
tal standpoint, our analyses represent the reality in which 
assessment of depressive symptoms may begin at varying 
time points within the lifespan. Our goal is to provide a 
more realistic conceptualization of the range and patterns 
of depressive symptoms that patients experience over time, 
which may help to guide clinical care for depression man-
agement among HIV-infected adults and ultimately lead to 
more targeted depression treatment interventions.
Methods
Data come from the Centers for AIDS Research (CFAR) 
Network of Integrated Clinical Systems (CNICS) cohort. 
The CNICS cohort includes over 31,000 HIV-infected adults 
in routine HIV clinical care across eight sites in the United 
States. Details about the CNICS cohort have previously been 
published [32]. Briefly, CNICS captures comprehensive 
clinical data through electronic medical records and other 
institutional data systems, including standardized diagno-
sis, medication prescription, laboratory, and demographic 
information. Participants in CNICS also complete self-
administered questionnaires, or patient‐reported outcomes 
(PROs), on touch-screen tablets as part of routine clinical 
visits [33, 34]. PROs are completed approximately every 
4–6 months, with variation based on individual patients’ 
clinical follow-up. All participants provide written informed 
consent to participate in CNICS. Ethical approval for the 
use of routinely collected clinical data was provided by the 
institutional review board at each CNICS site.
Study Population
We included HIV-infected adults enrolled in routine HIV 
care on or after PRO data collection began at their CNICS 
site (2005–2011, depending on site). Participants were 
followed from their first PRO measure (baseline) for up 
to 4 years or until administrative censoring (2014–2015, 
depending on site), whichever date came first. Follow-up 
time was divided into six-month intervals and the latest 
PRO measure in each interval was used in the analysis. In 
order to have sufficient information on depressive symp-
toms to describe trajectories over time, we only included 
participants who had a minimum of four, and a maximum 
of eight, consecutive six-month windows with a completed 
PRO. Additionally, we included only participants who had 
no more than one six-month interval without a PRO measure 
during their follow-up period. Group-based trajectory mod-
els allow for interim missing outcome data, while retaining 
all observed outcome measures, under the assumption that 
the data are missing completely at random [35]. Participants 
who died or were lost to follow-up prior completing four 
consecutive PRO measures within the allotted time interval 
were excluded.
Measures
Depressive symptoms were measured as part of routine 
PRO assessments as a continuous score using the Patient 
Health Questionnaire-9 (PHQ-9) [36]. The PHQ-9 asks 
about depressive symptoms over the last 2 weeks and ranges 
from a score of 0–27, with < 5 representing no depressive 
symptoms, 5–9 mild depressive symptoms, 10–14 moderate 
symptoms, 15–19 moderately severe symptoms, and ≥ 20–27 
severe depressive symptoms [36]. A PHQ-9 score ≥ 10 has 
88% sensitivity and specificity to detect a major depressive 
episode [36].
We considered a number of baseline clinical, HIV, sub-
stance use, mental health, and sociodemographic factors that 
may be associated with depressive symptom trajectory group 
membership. All measures were taken during a participant’s 
first PRO measure or at CNICS enrollment. CNICS PROs 
include validated measures of ART adherence (Adult AIDS 
Clinical Trials Unit Adherence Instrument, defined as no 
missed doses in the past week [37]), panic disorder (PHQ-
5, defined as none, some panic disorder symptoms, or panic 
disorder over the last 4 weeks [38]), high risk alcohol use 
over the last year (Alcohol Use Disorders Identification Test 
(AUDIT), defined as AUDIT-C score > 4 for males and > 3 
for females [39]), and illicit drug use, excluding marijuana 
(Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST), defined as none, past, or current [40, 41]).
In addition to PRO measures, CNICS also collects soci-
odemographic and clinical information which may influ-
ence depressive symptom trajectory group membership. 
Self-reported race/ethnicity (white, black, Hispanic, or 
other) and risk factors for HIV acquisition (male-to-male 
sexual contact (MSM), heterosexual contact, intravenous 
drug use (IDU) or other) were collected from participants’ 
medical records. Information on whether a participant had 
an active antidepressant prescription was also taken from 
participants’ medical records. CNICS also captures previ-
ous clinician-documented mental health, hypertension, and 
diabetes-related diagnoses in the medical record. A prior 
mental health disorder was defined as any previous men-
tal health-related diagnosis, including anxiety, depression, 
bipolar disorder, post-traumatic stress disorder (PTSD), 
psychosis, or other personality or mood disorders at the 
time of a patient’s first PRO measure. We defined a prior 
hypertension or diabetes comorbidity as any previous medi-
cal diagnosis related to hypertension or diabetes at the time 
of a patient’s first PRO measure. Information on clinician-
documental mental health, diabetes or hypertension related 
diagnoses prior to entry into CNICS care was not available. 
We used single mean imputation to fill in all missing base-
line covariate values (< 5% for all variables, except for illicit 
drug use which was 9%).
Participants entering CNICS care with a prior HIV diag-
nosis and treatment history may differ in their depressive 
symptom trajectories from patients receiving a new HIV 
diagnosis and starting treatment for the first time. Unfor-
tunately, information on HIV care prior to entering CNICS 
is not available in our data. To try to approximate which 
participants may have been new to HIV care, we indexed 
participants according to whether they had recently entered 
CNICS care (yes/no) and whether they had recently entered 
CNICS care and additionally had evidence of prior recent 
care (yes/no). We categorized participants as recently enter-
ing CNICS care if their baseline PRO assessment was com-
pleted ≤ 6 months after their initial CNICS visit. Participants 
with a baseline PRO > 6 months after their initial CNICS 
visit were categorized as not recently entering CNICS care. 
Participants who had recently entered CNICS care and had 
a detectable viral load within 28 days of CNICS entry were 
categorized as having no evidence of prior recent care. 
Participants with an undetectable or no recorded viral load 
within 28 days of CNICS entry or who had not recently 
entered CNICS care were considered to have evidence of 
prior recent care.
Statistical Analysis
The goals of this study were to (1) describe trajectories of 
depressive symptoms separately among HIV-infected men 
and women currently in HIV care, and (2) explore base-
line characteristics associated with membership in a par-
ticular trajectory group for HIV-infected men and women. 
Since depressive symptoms are more common among HIV-
infected women [42] and their depressive symptom trajecto-
ries may differ from those of men, we stratified all analyses 
by gender. We used group-based latent trajectory models, 
which identify clusters of individuals who have similar 
longitudinal patterns of an outcome [35, 43], to describe 
trajectories of depressive symptoms over time [35, 44]. We 
used the censored normal specification of the group-based 
trajectory model to predict the mean depressive symptoms 
score in each trajectory group over time, accounting for clus-
tering at the minimum (0) and maximum [27] PHQ-9 values 
[35, 43, 44]. We specified a random intercept to account 
for 
within-participant correlation in depressive symptom scores 
over time. All statistical analyses were conducted in SAS 
version 9.4 (SAS Institute, Cary, NC).
The selection of a best-fitting trajectory model within 
each gender involved two steps. First, we selected the num-
ber of trajectory groups. A priori, we decided to explore a 
maximum of five trajectory groups to ensure clinical util-
ity and interpretability. All trajectory groups were mod-
eled using cubic polynomial terms during this step, and the 
Bayesian Information Criterion (BIC) was used to select the 
model with the best fit [35]. Second, after we had selected 
the number of trajectory groups, the optimal functional 
form (constant vs. linear vs. quadratic vs. cubic) for each 
trajectory group was selected based on model fit using BIC 
and graphical inspection of the data. In this second step, we 
included parameter estimates from step 1 as start values for 
all model parameters to improve maximum likelihood esti-
mation [35, 43]. While the goal of our analysis was primar-
ily descriptive and exploratory, we assessed the adequacy 
of each group-based trajectory model by (1) examining 
whether the estimated probability of group membership cor-
responded to the proportion of participants assigned to each 
group based on the model-estimated posterior probability 
of group membership and (2) assessing if the median of the 
posterior probabilities of group membership was ≥ 0.70 for 
each group [35].
We used a second two-stage model building process to 
identify baseline predictors of trajectory group membership 
[35]. First, we identified important predictors of trajectory 
group membership using backwards elimination, from a mul-
tivariable multinomial logistic regression model in which 
the outcome was trajectory group (defined for each partici-
pant as the group with the maximum posterior probability 
of group membership in the best-fitting trajectory model 
described above), and all candidate predictors included as 
explanatory variables. Predictor variables with the largest 
Type 3 Analysis of Effects p-values were removed first until 
all covariates had at least one category with a p value ≤ 0.10 
[35]. Next, indicators for covariates identified in step 1 were 
included in a multivariable group-based trajectory model to 
account for probabilities of group membership and covari-
ance between parameter estimates, in order to ensure cor-
rect standard errors and 95% confidence interval coverage. 
Due to limited sample size, we collapsed some three-level 
variables (drug use and panic disorder) into binary variables 
(any panic symptoms versus no symptoms and current or 
past drug use versus no use). For all models including base-
line predictors, the group with “low” depressive symptoms 
(the largest trajectory group) was the referent.
We additionally conducted two descriptive analyses and 
one secondary analysis. First, in order to describe charac-
teristics of each trajectory group, we assigned each partici-
pant to the trajectory group for which he or she had the 
highest predicted posterior probability of group member-
ship (e.g. most likely trajectory group) from the best fitting 
group-based trajectory model and examined the distribution 
of baseline characteristics across groups [35]. Second, in 
order to understand how depressive symptom scores may 
have changed over time due to antidepressant treatment, we 
descriptively examined the distribution of depressive symp-
tom scores and the proportion of participants with an anti-
depressant prescription over time, stratified by most likely 
trajectory group and gender. In a secondary analysis, we 
compared depressive symptom trajectories among the entire 
study population and those recently entering CNICS care, 
stratified by gender. This secondary analysis was designed to 
determine whether different trajectory groups emerge when 
trajectory measurement starts near the time of entry into 
CNICS care, as compared to the more variable time origins 
with respect to care entry in the main analysis.
Results
Baseline Characteristics
Overall, 292 women (16%) and 1493 men (84%) were 
included in our analysis (Table 1). The majority of women 
were Black, non-Hispanic (64%) and reported contracting 
HIV through heterosexual contact (86%). Men were predom-
inately white, non-Hispanic (54%) and reported contracting 
HIV though male-to-male sexual contact (75%). Over a third 
of participants (35% of women and 36% of men) were new 
to CNICS care and approximately one fifth of both women 
(19%) and men (23%) overall had recently entered CNICS 
care with no evidence of prior recent care. Approximately 
40% of all participants had a detectable viral load within 
60 days of their first PRO measure.
Mental health issues and substance use at baseline were 
common in our cohort. Overall, 35% of women and 27% 
of men had an antidepressant prescription, 29% of women 
and 26% of men had moderate to more severe depressive 
symptoms (PHQ-9 ≥ 10), and 58% of women and 50% of 
men had a previous mental health diagnosis at their first 
PRO measure. Drug use was more common among men: 
37% of men reported past drug use and 15% reported current 
drug use, compared to 28% and 10% of women, respectively. 
High-risk alcohol use was reported by 11% of women and 
13% of men (Table 1).
Participants included in our analysis were largely similar 
to all participants in CNICS who had their first PRO measure 
during the study period but did not meet full inclusion crite-
ria, and to all participants entering CNICS during the study 
period (who may not necessarily have had a PRO measure). 
However, antidepressant use and previous mental health 
diagnoses were less common among all participants entering 
CNICS care during the study period, than among partici-
pants included study population and participants with a PRO 
measure who did not meet inclusion criteria (Table S1).
Description of Trajectory Groups
We identified four trajectory groups that were common to 
both men and women, with a fifth group emerging among 
men only (Fig. 1). We labeled the four groups identified 
in both men and women as: “low” depressive symptoms 
(exhibited by 56% of women and 61% of men), “mild to 
moderate” (24% of women and 14% of men), “improv-
ing” (14% of women and 13% of men) and “severe” (6% of 
women and 7% of men). In men, 5% followed a fifth pattern, 
which we termed “rebounding”.” The distribution of depres-
sive symptoms scores within comparable trajectory groups 
was similar across men and women over time (Fig. 2). The 
proportion of participants with an interim missing depres-
sive symptom measure was similar across trajectory groups 
for both men and women. For both men and women, the esti-
mated probability of group membership and the proportion 
of participants assigned to each trajectory group based on 
the model’s estimated posterior probability were reasonably 
close and the median posterior probability of group mem-
bership were ≥ 0.70 for all groups, suggesting both models 
adequately captured trajectories of depressive symptoms 
(Tables S2, S3).
For both women and men, median PHQ-9 values in the 
low trajectory group were consistent with very mild to no 
depressive symptoms over time (Fig. 1). Median PHQ-9 
values in the mild to moderate trajectory started in the mild 
range and increased to moderate depressive symptoms over 
time, with slightly higher scores among women across time. 
Men and women in the improving trajectory group had 
median PHQ-9 values consistent with moderate or moderate 
severe depressive symptoms at the start of follow-up, which 
improved to mild symptoms over time. Men in the rebound-
ing trajectory group also had moderate severe depressive 
symptoms at baseline, which improved but later returned 
to moderate levels over follow-up. Finally, median PHQ-9 
values for men and women in the severe trajectory group 
were consistent with moderate severe depressive symptoms 
throughout the follow-up period. Approximately 20–25% of 
participants experienced at least moderate depressive symp-
toms throughout most of the follow-up period. A secondary 
analysis restricted to participants recently entering CNICS 
care, trajectory groups were similar in shape and distribution 
to the primary analysis.
Antidepressant Use Over Time
Antidepressant prescription patterns varied across trajec-
tory groups, and not always in accordance with depressive 
Table 1  Sociodemographic, 
mental health and HIV clinical 
characteristics at first patient 
reported outcome (PRO) 
measure for 1785 HIV-infected 
men and women in CNICS, 
2005–2014
Characteristic Men Women
N = 1493(83.6) N = 292 (16.4)
N (%) or Median (IQR) N (%) or Median (IQR)
Site
 Fenway 70 (4.7) 3 (1.0)
 UAB 756 (50.6) 203 (69.5)
 UNC 5 (0.3) 3 (1.0)
 UCSD 381 (25.5) 50 (17.1)
 UCSF 130 (8.7) 14 (4.8)
 UW 151 (10.1) 19 (6.5)
Year of first PRO 2011 (2009, 2012) 2010 (2009, 2012)
Recently entered CNICS  Carea
 No 949 (63.6) 191 (65.4)
 Yes 544 (36.4) 101 (34.6)
Recently entered CNICS care with no evidence of prior recent  careb
 No 1155 (77.4) 236 (80.8)
 Yes 338 (22.6) 56 (19.2)
Time from entry into CNICS to first PRO, days 463 (82, 2,214) 659 (100, 2,770)
Age 44 (36, 51) 46 (39, 52)
Race/ethnicity
 White, non-Hispanic 809 (54.2) 74 (25.3)
 Black, non-Hispanic 440 (29.5) 185 (63.6)
 Hispanic 203 (13.6) 26 (8.9)
 Other 41 (2.8) 7 (2.4)
HIV risk group
 IDU 192 (12.9) 30 (10.3)
 MSM 1112 (74.5) 7 (2.4)e
 Heterosexual 172 (11.5) 251 (86.0)
 Other 17 (1.1) 4 (1.4)
Depression status
 Not depression (PHQ-9 < 10) 1106 (74.1) 207 (70.9)
 Depressed (PHQ-9 ≥ 10) 387 (25.9) 85 (29.1)
Panic disorder
 No symptoms 1086 (72.7) 216 (74.0)
 Some symptoms 241 (16.1) 36 (12.3)
 Panic disorder 166 (11.1) 40 (13.7)
Antidepressant use
 No antidepressant prescription 1093 (73.2) 190 (65.1)
 Antidepressant prescription 400 (26.8) 102 (34.9)
Drug use
 No use 726 (48.6) 181 (62.0)
 Current use 217 (15.4) 29 (9.9)
 Past use 550 (36.8) 82 (28.1)
Alcohol  usec
 No high risk alcohol use 1298 (86.9) 259 (88.7)
 High risk alcohol use 195 (13.1) 33 (11.3)
Previous mental health diagnosis
 No 750 (50.2) 122 (41.8)
 Yes 743 (49.8) 170 (58.2)
Previous medical diagnosis
 No 1077 (72.1) 192 (65.8)
symptom severity (Fig. 2). In the mild to moderate trajec-
tory groups, antidepressant prescription increased slightly 
as depressive symptoms increased for men and women. 
Compared to men, antidepressant prescription was more 
common among women in several trajectory groups (mild 
to moderate, improving, and severe groups). Further, antide-
pressant prescription increased in the severe trajectory group 
over time only among women. Overall, antidepressant pre-
scription did not change dramatically or consistently over 
time across trajectory groups with more severe depressive 
Table 1  (continued) Characteristic Men Women
N = 1493(83.6) N = 292 (16.4)
N (%) or Median (IQR) N (%) or Median (IQR)
 Yes 416 (27.9) 100 (34.2)
ART use and  adherenced
 Adherent, on ART 1021 (68.4) 187 (64.0)
 Not adherent, on ART 140 (9.4) 37 (12.7)
 Off ART 332 (22.2) 68 (23.3)
CD4 count, cells/mmc 462 (291, 632) 487 (314, 683)
Viral load suppression (< 50 copies/mL)
 Undetectable viral load 851 (57.0) 175 (59.9)
 Detectable viral load 642 (43.0) 117 (40.1)
PRO patient-reported outcomes, MSM: men who have sex with men, IDU intravenous drug use
a Defined as participants who had their baseline PRO measure within 6 months of their initial CNICS visit
b Defined as participants who had their baseline PRO measure within 6 months of their initial CNICS visit 
and had a detectable viral load within 28 days of entering CNICS care
c Defined as Alcohol Use Disorders Identification Test (AUDIT) score > 4 for males and > 3 for females
d Adherence defined as no missed medication doses in the last week
e A small proportion of persons identifying as ‘female’ at entry into CNICS care endorsed MSM as their 
primary risk factor for HIV infection. Due to the small number, this group was combined with the “Other” 
category in statistical analyses
Fig. 1  Depressive symptom trajectories for 292 HIV-infected women 
and 1493 HIV-infected men in care in CNICS between 2005 and 
2014. Depressive symptoms were measured using the Patient Health 
Questionnaire-9 (PHQ-9). Solid lines indicate observed mean depres-
sive symptom scores and dotted lines indicated predicted mean 
depressive symptom score in each trajectory group, as estimated 
from a group-based trajectory model using a censored normal speci-
fication and random intercept. For women, the “low” trajectory was 
modeled using a linear term, the “mild to moderate” trajectory using 
a quadratic term, and the “improving” and “severe” trajectories were 
modeled using a cubic term. For men, the “low” trajectory group was 
modeled using a linear term, the “mild to moderate” trajectory using 
a quadratic term, the “rebounding” trajectory using a cubic term, the 
“improving” trajectory using a quadratic term, and the “severe” tra-
jectory using a cubic term
Fig. 2  Distribution of Patient Health Questionne-9 (PHQ-9) depres-
sive symptoms scores and proportion receiving antidepressant treat-
ment prescription over time, stratified by gender and assigned trajec-
tory group (based on each participant’s highest predicted posterior 
group-membership probability). Box and whisker plots of depressive 
symptoms scores indicate median and interquartile range values in 
the box, minimum and maximum values in the whiskers, and outliers 
in the circles
symptoms, including among participants in the improving 
trajectory group. For both men and women, antidepressant 
prescription remained well below 60% for much of the fol-
low-up period.
Baseline Predictors of Trajectory Group Membership
Multivariable associations between baseline covariates 
and trajectory group membership for men and women are 
reported in Fig. 3. Additional descriptive profiles of trajec-
tory group membership for both men and women are avail-
able in Tables S2 and S3. Among women, compared to being 
in the low trajectory group, those in the mild to moderate 
trajectory group were more likely to have any panic disorder 
symptoms (OR 5.36, 95% CI 1.91, 15.00), or report current 
or past drug use (OR 2.53, 95% CI 1.17, 5.44). Those in the 
improving trajectory group were more likely to be black, 
non-Hispanic (OR 5.26, 95% CI 1.14, 24.24) or have any 
panic disorder symptoms (OR 25.49, 95% CI 8.01, 81.12). 
Compared to those in the low group, those in the severe 
trajectory group were more likely to have a previous mental 
health diagnosis (OR 7.91, 95% CI 0.99, 62.82) or have any 
panic disorder symptoms (OR 16.07, 95% CI 3.96, 65.27).
Among men, compared to those in the low trajectory 
group, those in the mild to moderate group were less likely 
to have recently entered CNICS care with no evidence of 
prior recent care (OR 0.32, 95% CI 0.14, 0.74), and were 
more likely to have recently entered CNICS care (OR 2.22, 
95% CI 1.22, 4.05), have any panic disorder symptoms (OR 
3.27, 95% CI 1.97, 5.43), have an antidepressant prescription 
(OR 1.95, 95% CI 1.21, 3.14), report current or past drug 
use (OR 1.68, 95% CI 1.07, 2.64), have a previous mental 
health diagnosis (OR 2.50, 95% CI 1.55, 4.05) and be non-
adherent to ART (OR 3.18, 95% CI 1.70, 5.98) at baseline. 
Those in the rebounding trajectory group were more likely 
to be Hispanic (OR 3.82, 1.67, 8.74), report contracting HIV 
through IDU (OR 2.68, 1.13, 6.35), have recently entered 
CNICS care (OR 4.32, 95% CI 1.70, 10.92), have any panic 
disorder symptoms (OR 8.65, 95% CI 4.07, 18.38), and to be 
non-adherent to ART (OR 3.43, 95% CI 1.18, 9.97). Those 
in the improving trajectory group were more likely to be 
Hispanic (OR 2.31, 95% CI 1.24, 4.32), have any panic dis-
order symptoms (OR 7.57, 95% CI 4.73, 12.13), have an 
antidepressant prescription (OR 2.67, 95% CI 1.63, 4.39), 
report current or past drug use (OR 1.63, 95% CI 1.02, 2.59), 
have a previous mental health diagnosis (OR 2.39, 95% CI 
1.45, 3.93), be non-adherent to ART (OR 3.66, 95% CI 1.86, 
7.20), and to be off ART (OR 1.97, 95% CI 1.10, 3.52). 
Compared to those in the low trajectory group, those in the 
severe trajectory group were more likely to have any panic 
Fig. 3  Multivariable odds ratios and 95% confidence intervals for 
the relationship between baseline covariates and membership in each 
depressive symptoms trajectory group, compared to the low depres-
sive symptom trajectory group, for HIV-infected women (4 groups) 
and men (5 groups). Each covariate represents a comparison of that 
factor to all other categories of that variable based on a trajectory 
model that accounts for group membership probabilities and covari-
ance across parameter values, to ensure correct standard errors and 
95% confidence interval coverage. 1Defined as participants who had 
their baseline PRO measure ≤ 6 months after their initial CNICS visit 
and had a detectable viral load within 28  days of entering CNICS 
care. 2Defined as participants who had their baseline PRO meas-
ure ≤ 6 months after their initial CNICS visit. 3Defined as < 50 copies/
mL; rx = prescription, dx = diagnosis
disorder symptoms (OR 14.62, 95% CI 7.98, 26.76), have an 
antidepressant prescription (OR 2.86, 95% CI 1.58, 5.15), 
have a previous mental health diagnosis (OR 2.75, 95% CI 
1.52, 4.98), be non-adherent to ART (OR 3.72, 95% CI 1.63, 
8.47), and to be off ART (OR 2.26, 95% CI 1.09, 4.69).
Discussion
In our population of HIV-infected adults in routine HIV care, 
we identified four depressive symptom trajectory groups for 
HIV-infected women and five depressive symptom trajec-
tories for HIV-infected men over a median 30 months of 
follow-up. For both men and women, depressive symptom 
trajectories ranged from almost no depressive symptoms to 
severe depressive symptoms. With the exception of the low 
and severe depressive symptom trajectory groups, depres-
sive symptom severity changed considerably over the follow-
up period. Over 2–4 years of follow-up, nearly a quarter of 
both HIV-infected men and women experienced moderate 
to more severe depressive symptoms. Changes in depres-
sive symptom severity did not appear to be driven primarily 
by changes in antidepressant prescription, with only slight 
increases in antidepressant prescription being noted in the 
mild to moderate and severe (women only) trajectory groups. 
Overall, antidepressant prescription remained below 60% 
for much of the follow-up period, despite the high level of 
depressive symptoms in several trajectory groups.
Patterns of depressive symptom trajectories were rela-
tively similar between HIV-infected men and women, with 
four similar trajectories emerging (low, mild to moderate, 
improving, and severe) and comparable proportions of the 
population in each trajectory. A fifth, rebounding, trajectory 
group was identified among HIV-infected men, but included 
just 5% of men. The distinct trajectories we identified sug-
gest that HIV-infected adults’ experiences of depressive 
symptoms over time vary considerably, but may be compa-
rable across genders. While some participants had mild to 
moderate or improving depressive symptoms, which may 
respond to antidepressant or counseling treatment [45], oth-
ers experienced severe, chronic symptoms that may be part 
of a more complex mental health picture requiring additional 
resources and treatment [46–48]. For over half of the partici-
pants in our study, depressive symptoms were consistently 
low to absent throughout the follow-up period, suggesting 
that less frequent depressive symptom screening may be an 
option for participants with sustained low depressive symp-
toms scores.
In our study, comorbid mental health conditions were 
associated with membership in trajectory groups with more 
severe depressive symptoms. In multivariable analyses for 
both men and women, panic disorder symptoms and hav-
ing a previous mental health diagnosis were associated with 
membership in more severe or dynamic depressive symptom 
trajectory groups. Being on an antidepressant at baseline was 
also associated with membership in more severe depressive 
symptom trajectory groups for men; effect estimates were 
elevated but imprecise among women. Having a previous 
mental health diagnosis was most strongly associated with 
membership in the severe trajectory group for both men 
and women. However, no clear pattern of factors emerged 
to distinguish participants in the improving, rebounding 
(men only), and severe trajectory groups from one another. 
Depression has been reported as comorbid with other mental 
health condition in both HIV-infected and uninfected adults 
[49, 50]. Our study further suggests that participants with 
comorbid mental health conditions may be likely to experi-
ence more severe and persistent depressive symptoms.
We also observed associations for several clinical and 
socio-demographic factors with trajectory group member-
ship. Across both men and women, there was some limited 
evidence that substance use was associated with member-
ship in more severe depressive symptom trajectory groups 
and that racial minorities were more likely to be in improv-
ing or rebounding trajectory groups. Among men, baseline 
reports of poor ART adherence or being off ART were also 
associated with membership in more severe depressive 
symptom trajectory groups. Since our population includes 
HIV-infected adults currently in care, these findings may 
reflect adherence problems or delayed ART use resulting 
from depressive symptoms. Among men, participants who 
were new to CNICS were also more likely to be in the mild 
to moderate or rebounding trajectory groups, which may 
indicate increased detection of depressive symptoms among 
participants recently entering care in CNICS, where depres-
sion screening is routine.
Our analysis also confirmed the gap in antidepressant 
treatment that has been described among HIV-infected 
adults with depression [51.] Just over half of participants in 
the mild to moderate trajectory groups were on antidepres-
sant medications throughout follow-up. In addition, women 
were more likely to be treated than men in several trajectory 
groups [52]. Compared to men, antidepressant prescription 
was considerably higher among women in the improving and 
severe trajectory groups. These findings raise the question 
of whether more participants, and in particular more men, 
would have experienced improving or remitting depressive 
symptoms if they had been treated with antidepressants. 
Interestingly, antidepressant prescription increased slightly 
over time for both men and women in the mild to moder-
ate trajectory group, suggesting a possible clinical response 
in antidepressant prescription to increasing depressive 
symptoms.
There are several limitations to our analysis. First, small 
sample size, particularly for women, may limit the gener-
alizability of our findings. However, participants in our 
analysis were fairly similar to participants in the larger 
CNICs cohort (Table S1). Limited sample size also led 
to imprecise estimates for many predictors of trajectory 
group membership and reported estimates should be inter-
preted with caution. In addition, the limited number of 
women in our analysis (and more generally, in CNICS) 
precluded identifying a greater range of predictors of tra-
jectory group membership in women, and may have lim-
ited our ability to detect the existence of a fifth trajectory 
group. Second, while we identified several predictors of 
trajectory group membership, it was difficult to distin-
guish between participants who were likely to improve, 
rebound, or experience chronic, severe depression. More 
detailed data on mental health comorbidities or access to 
counseling services may help to further distinguish these 
groups. We note the use of mean imputation of missing 
baseline data as a limitation. Finally, information on how 
counseling or other behavioral therapy may influence 
depressive symptom trajectories over time was not avail-
able in our data.
Our study focused on identifying depressive symptom 
trajectories in a real-world population currently in HIV care. 
In order to obtain internally valid estimates of depressive 
symptom trajectories over time, we restricted our study pop-
ulation to individuals with a minimum of four consecutive 
depressive symptom measures. However, since persons with 
depression may be less likely to attend HIV care visits [53], 
this may limit the generalizability of our findings. Further, 
our analysis included all HIV-infected individuals in care. 
Depressive symptom trajectories were similar between those 
recently entering CNICS care and the entire study popula-
tion. However, it is possible that depressive symptom tra-
jectories may be more severe or variable in a population 
of persons newly diagnosed with HIV. Additional work is 
needed to understand how depressive symptom trajectories 
may differ among populations newly diagnosed with HIV or 
newly entering HIV care. Similarly, dual-trajectory analyses 
could provide important future insights on concomitant pat-
terns of depressive symptoms with antidepressant use, viral 
load suppression, and HIV risk behaviors.
Our results have several important clinical implications. 
We found that not all depressive symptoms follow the same 
trajectory. When patients present with depressive symptoms, 
understanding the trajectory their depressive symptoms are 
likely to follow can help to guide clinical care. In particular, 
we found that comorbid mental health conditions are con-
sistently associated with more severe or dynamic depressive 
symptom trajectories. For patients with comorbid mental 
health conditions, addressing depression alone is unlikely to 
be effective and a more comprehensive strategy addressing 
the full range of mental health needs may be required. In 
addition, in order to decrease depressive symptom sever-
ity over time, greater access to antidepressant treatment or 
behavioral therapy among patients with moderate or more 
severe depressive symptoms is urgently needed.
Conclusions
Not all depressive symptoms are the same. Over a median 
30 months of follow-up, HIV-infected adults who were in 
HIV care followed markedly different—and in many cases, 
dynamic—depressive symptom trajectories ranging from few 
or almost no depressive symptoms to chronic, severe depres-
sive symptoms. For both HIV-infected men and women, a size-
able proportion of the population experienced some degree of 
depressive symptoms throughout the follow-up period, high-
lighting the pressing need for evidence-based antidepressant 
treatment or behavioral therapy in this population. Our study 
focused on identifying depressive symptom trajectories in a 
real-world population currently in HIV care. Further research 
is needed to understand how depressive symptom trajectories 
may differ among populations newly diagnosed with HIV or 
newly entering HIV care; to distinguish those whose depressive 
symptoms are likely to improve, rebound, or be chronic and 
severe; and to understand what additional factors contribute 
to chronic severe depressive symptoms. Such information will 
pave the way for more targeted health interventions to address 
patients’ unique mental needs, and ultimately reduce depressive 
symptoms among HIV-infected adults.
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